BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31160237)

  • 1. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
    Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
    Moreau P; Joshua D; Chng WJ; Palumbo A; Goldschmidt H; Hájek R; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Aggarwal S; Feng S; Dimopoulos MA
    Leukemia; 2017 Jan; 31(1):115-122. PubMed ID: 27491641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
    Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L
    Curr Probl Cancer; 2024 Jun; 50():101078. PubMed ID: 38547609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
    Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
    Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA
    Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
    Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
    J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
    Ailawadhi S; Sexton R; Lentzsch S; Abidi MH; Voorhees PM; Cohen AD; Rohren EM; Heitner S; Kelly K; Mackler NJ; Baer DM; Hoering A; Durie B; Orlowski RZ
    Clin Cancer Res; 2020 Aug; 26(15):3969-3978. PubMed ID: 32299820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
    Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
    Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
    Martino EA; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Vigna E; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pettine L; Vincelli ID; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Reddiconto G; Maroccia A; Franceschini L; Bertuglia G; Nappi D; Barbieri E; Gamberi B; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P; Gentile M
    Hematol Oncol; 2024 Jul; 42(4):e3290. PubMed ID: 38818978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
    Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
    J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
    Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
    Jacobus SJ; Rajkumar SV; Weiss M; Stewart AK; Stadtmauer EA; Callander NS; Dreosti LM; Lacy MQ; Fonseca R
    Blood Cancer J; 2016 Jul; 6(7):e448. PubMed ID: 27471864
    [No Abstract]   [Full Text] [Related]  

  • 13. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
    Zou Y; Ma X; Yu H; Hu C; Fan L; Ran X
    Oncotarget; 2017 Jun; 8(24):39805-39817. PubMed ID: 27458170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
    Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
    Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
    Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
    Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
    He J; Berringer H; Heeg B; Ruan H; Kampfenkel T; Dwarakanathan HR; Johnston S; Mendes J; Lam A; Bathija S; Mackay EK
    Adv Ther; 2022 Sep; 39(9):4230-4249. PubMed ID: 35876974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
    Barilà G; Quaglia FM; Furlan A; Pescosta N; Bonalumi A; Marcon C; Pascarella A; Tinelli M; De March E; Lico A; Sartori R; Clissa C; De Sabbata G; Nappi D; Porrazzo M; De Marchi R; Pavan L; Tosetto A; Gherlinzoni F; Krampera M; Bassan R; Patriarca F; Semenzato G; Zambello R
    Ann Hematol; 2024 Jan; 103(1):125-132. PubMed ID: 37731147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
    J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
    Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT; Nooka AK; Harvey RD; Lonial S
    Blood Cancer J; 2019 Jan; 9(1):3. PubMed ID: 30610196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.